ClariVest Asset Management’s Iovance Biotherapeutics IOVA Stock Holding History

ClariVest Asset Management’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$337	Hold	42	–	–	﹤0.01%	826
2024 Q2	$337	Sell	42 -122	-74%	-$1.31K	﹤0.01%	826
2024 Q1	$2.43K	Buy	164 +42	+34%	+$489	﹤0.01%	546
2023 Q4	$992	Hold	122	–	–	﹤0.01%	659
2023 Q3	$0	Sell	122 -95	-44%	-$620	﹤0.01%	807
2023 Q2	$1K	Buy	217 +52	+32%	+$372	﹤0.01%	611
2023 Q1	$1K	Hold	165	–	–	﹤0.01%	663
2022 Q4	$1K	Hold	165	–	–	﹤0.01%	631
2022 Q3	$2K	Buy	+165	New	+$1.9K	﹤0.01%	535
2021 Q2	–	Sell	-9	Closed	–	–	791
2021 Q1	$0	Hold	9	–	–	﹤0.01%	769
2020 Q4	$0	Hold	9	–	–	﹤0.01%	786
2020 Q3	$0	Sell	9 -43,871	-100%	-$1.34M	﹤0.01%	803
2020 Q2	$1.2M	Buy	43,880 +7,067	+19%	+$232K	0.03%	301
2020 Q1	$1.1M	Buy	+36,813	New	+$976K	0.03%	283

Other funds holding IOVA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

MFM

MHR Fund Management New York $1.37B AUM 68.35% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

HRCM

Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

ClariVest Asset Management's IOVA Position: Q3 2024 in Review

ClariVest Asset Management held its Iovance Biotherapeutics (IOVA) position steady in Q3 2024 at 42 shares worth $337. The position accounts for ﹤0.01% of the portfolio, ranked #826.

ClariVest Asset Management first reported a position in IOVA in Q1 2020 and has held it in 14 quarters since. The position peaked at $1.2M in Q2 2020. 286 funds tracked by Wall St. Rank hold IOVA as of Q3 2024.

ClariVest Asset Management held 42 shares of Iovance Biotherapeutics worth $337 as of Q3 2024.
ClariVest Asset Management left its Iovance Biotherapeutics share count unchanged in Q3 2024.
Iovance Biotherapeutics made up ﹤0.01% of ClariVest Asset Management's portfolio in Q3 2024, its #826 holding.
ClariVest Asset Management first reported a position in Iovance Biotherapeutics in Q1 2020 and has held it in 14 quarters since.
ClariVest Asset Management's Iovance Biotherapeutics position peaked at $1.2M in Q2 2020.
286 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q3 2024.

Based on ClariVest Asset Management's 13F filing for Q3 2024, filed 12 Nov 2024.